Source link : https://www.newshealth.biz/health-news/sustained-control-with-new-mab-for-myasthenia-gravis/
SAVANNAH, GEORGIA – The investigational monoclonal antibody nipocalimab (Johnson & Johnson) is associated with significant improvement in patients with generalized myasthenia gravis (gMG) over a 24-week period, according to topline results from the phase 3 VIVACITY-MG3 study. The VIVACITY-MG3 trial is the first registrational study of a neonatal fragment crystallizable receptor (FcRn) blocker to show […]
Author : News Health
Publish date : 2024-10-16 19:07:09
Copyright for syndicated content belongs to the linked Source.